← All trials
NCT05764915
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2023
- Primary completion
- Feb 20, 2025
- Completion date
- Aug 2, 2025
- First posted
- Mar 13, 2023
- Last posted
- Mar 13, 2023
- Enrollment
- 56
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Regor Pharmaceuticals Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.